These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

411 related items for PubMed ID: 33387727

  • 1. Afatinib in EGFR TKI-naïve patients with locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer: Interim analysis of a Phase 3b study.
    de Marinis F, Laktionov KK, Poltoratskiy A, Egorova I, Hochmair M, Passaro A, Migliorino MR, Metro G, Gottfried M, Tsoi D, Ostoros G, Rizzato S, Mukhametshina GZ, Schumacher M, Novello S, Dziadziuszko R, Tang W, Clementi L, Cseh A, Kowalski D.
    Lung Cancer; 2021 Feb; 152():127-134. PubMed ID: 33387727
    [Abstract] [Full Text] [Related]

  • 2. An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.
    Park K, Kim JS, Kim JH, Kim YC, Kim HG, Cho EK, Jin JY, Kim M, Märten A, Kang JH.
    BMC Cancer; 2021 Jul 12; 21(1):802. PubMed ID: 34253172
    [Abstract] [Full Text] [Related]

  • 3. A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naïve Patients with EGFRm+ NSCLC: Final Analysis, with a Focus on Patients Enrolled at Sites in China.
    Tu HY, Feng J, Shi M, Zhao J, Wang Y, Chang J, Wang J, Cheng Y, Zhu J, Tan EH, Li K, Zhang Y, Lee V, Yang CT, Su WC, Lam DC, Srinivasa BJ, Rajappa S, Ho CL, Lam KC, Hu Y, Bondarde SA, Liu X, Tian Y, Xue Z, Cseh A, Huang DC, Zhou C, Wu YL.
    Target Oncol; 2022 Jan 12; 17(1):1-13. PubMed ID: 35020119
    [Abstract] [Full Text] [Related]

  • 4. Afatinib as First-Line Treatment in Asian Patients with EGFR Mutation-Positive NSCLC: A Narrative Review of Real-World Evidence.
    Lu S, Shih JY, Jang TW, Liam CK, Yu Y.
    Adv Ther; 2021 May 12; 38(5):2038-2053. PubMed ID: 33730350
    [Abstract] [Full Text] [Related]

  • 5. A phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small-cell lung cancer (KTORG1402).
    Yokoyama T, Yoshioka H, Fujimoto D, Demura Y, Hirano K, Kawai T, Kagami R, Washio Y, Ishida T, Kogo M, Tomii K, Okuno T, Akai M, Hirabayashi M, Nishimura T, Nakahara Y, Kim YH, Miyakoshi C, Yoshimura K, Hirai T, Kyoto Thoracic Oncology Research Group (KTORG).
    Lung Cancer; 2019 Sep 12; 135():175-180. PubMed ID: 31446992
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies.
    Passaro A, de Marinis F, Tu HY, Laktionov KK, Feng J, Poltoratskiy A, Zhao J, Tan EH, Gottfried M, Lee V, Kowalski D, Yang CT, Srinivasa BJ, Clementi L, Jalikop T, Huang DCL, Cseh A, Park K, Wu YL.
    Front Oncol; 2021 Sep 12; 11():709877. PubMed ID: 34307179
    [Abstract] [Full Text] [Related]

  • 8. A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027.
    Minegishi Y, Yamaguchi O, Sugawara S, Kuyama S, Watanabe S, Usui K, Mori M, Hataji O, Nukiwa T, Morita S, Kobayashi K, Gemma A.
    BMC Cancer; 2021 Mar 01; 21(1):208. PubMed ID: 33648453
    [Abstract] [Full Text] [Related]

  • 9. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group.
    Agraso S, Lázaro M, Firvida XL, Santomé L, Fernández N, Azpitarte C, Leon L, Garcia C, Hudobro G, Areses MC, Campos B, Quiroga N, García J, Casal J.
    Cancer Treat Res Commun; 2022 Mar 01; 33():100646. PubMed ID: 36335799
    [Abstract] [Full Text] [Related]

  • 10. Biomarker subset analysis of a phase IIIb, open-label study of afatinib in EGFR tyrosine kinase inhibitor-naive patients with EGFRm+ non-small-cell lung cancer.
    Zhao J, Bai H, Wang X, Wang Y, Duan J, Chen H, Xue Z, Tian Y, Cseh A, Huang DC, Wu YL, Wang J.
    Future Oncol; 2022 Apr 01; 18(12):1485-1497. PubMed ID: 35114807
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.
    Park K, Tan EH, O'Byrne K, Zhang L, Boyer M, Mok T, Hirsh V, Yang JC, Lee KH, Lu S, Shi Y, Kim SW, Laskin J, Kim DW, Arvis CD, Kölbeck K, Laurie SA, Tsai CM, Shahidi M, Kim M, Massey D, Zazulina V, Paz-Ares L.
    Lancet Oncol; 2016 May 01; 17(5):577-89. PubMed ID: 27083334
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study.
    Moran T, Taus A, Arriola E, Aguado C, Dómine M, Rueda AG, Calles A, Cedrés S, Viñolas N, Isla D, Palmero R, Sereno M, Diaz V, Juan O, Marsé R, Martorell PM, Sánchez Torres JM, Study Group for the Uncommon EGFR Mutations in Spain.
    Clin Lung Cancer; 2020 Sep 01; 21(5):428-436.e2. PubMed ID: 32461037
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Afatinib: a review of its use in the treatment of advanced non-small cell lung cancer.
    Keating GM.
    Drugs; 2014 Feb 01; 74(2):207-21. PubMed ID: 24435321
    [Abstract] [Full Text] [Related]

  • 18. Older patients with EGFR mutation-positive non-small cell lung cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study.
    Brueckl WM, Reck M, Schäfer H, Neben K, Griesinger F, Rawluk J, Krüger S, Kokowski K, Ficker JH, Möller M, Schueler A, Laack E.
    J Geriatr Oncol; 2023 Jan 01; 14(1):101394. PubMed ID: 36323612
    [Abstract] [Full Text] [Related]

  • 19. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam.
    Vu TH, Nguyen HTT, Dao LK, Duong CK, Nguyen CV, Doan TT, Nguyen HTT, Hoang HH, Dinh DK, Le GV, Vu TT, Truong MC, Nguyen LT.
    Asian Pac J Cancer Prev; 2021 May 01; 22(5):1581-1590. PubMed ID: 34048189
    [Abstract] [Full Text] [Related]

  • 20. Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.
    Ninomiya T, Nogami N, Kozuki T, Harada D, Kubo T, Ohashi K, Ichihara E, Kuyama S, Kudo K, Bessho A, Sakugawa M, Fujimoto N, Aoe K, Minami D, Sugimoto K, Ochi N, Takigawa N, Hotta K, Maeda Y, Kiura K.
    Jpn J Clin Oncol; 2021 Aug 01; 51(8):1269-1276. PubMed ID: 34115855
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.